1.Harris, WS, Mozaffarian, D, Lefevre, M et al. (2009) Towards establishing dietary reference intakes for eicosapentaenoic and docosahexaenoic acids. J Nutr 139, 804S–819S.
2.Del Gobbo, LC, Imamura, F, Aslibekyan, S et al. (2016) n-3 polyunsaturated fatty acid biomarkers and coronary heart disease: pooling project of 19 cohort studies. JAMA Intern Med 176, 1155–1166.
3.Harris, WS & von Schacky, C (2004) The Omega-3 Index: a new risk factor for death from coronary heart disease? Prev Med 39, 212–220.
4.Kleber, ME, Delgado, GE, Lorkowski, S et al. (2016) Omega-3 fatty acids and mortality in patients referred for coronary angiography. The Ludwigshafen risk and cardiovascular health study. Atherosclerosis 252, 175–181.
5.Harris, WS, Luo, J, Pottala, JV et al. (2017) Red blood cell polyunsaturated fatty acids and mortality in the women's health initiative memory study. J Clin Lipidol 11, 250–259.
6.Harris, WS, Tintle, NL, Etherton, MR et al. (2018) Erythrocyte long-chain omega-3 fatty acid levels are inversely associated with mortality and with incident cardiovascular disease: the Framingham heart study. J Clin Lipidol 12, 718–724.
7.Lai, HT, de Oliveira Otto, MC, Lemaitre, RN et al. (2018) Serial circulating omega 3 polyunsaturated fatty acids and healthy ageing among older adults in the cardiovascular health study: prospective cohort study. BMJ (Clin Res Ed) 363, 363:k4067.
8.Block, RC, Harris, WS & Pottala, JV. (2008) Determinants of blood cell omega-3 fatty acid content. Open Biomarkers J 1, 1–6.
9.Harris, WS, Kennedy, KF, Maddox, TM et al. (2016) Multiple differences between patients who initiate fish oil supplementation post-myocardial infarction and those who do not: the triumph study. Nutr Res 36, 65–71.
10.Burr, ML, Fehily, AM, Gilbert, JF et al. (1989) Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (dart). Lancet 2, 757–761.
11.Marchioli, R, Barzi, F, Bomba, E et al. (2002) Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano Per Lo Studio Della Sopravvivenza Nell'infarto Miocardico (Gissi)-Prevenzione. Circulation 105, 1897–1903.
12.Investigators, G-H (2008) Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the Gissi-Hf Trial): a randomised, double-blind, placebo-controlled trial. Lancet 372, 1223–1230.
13.Yokoyama, M, Origasa, H, Matsuzaki, M et al. (2007) Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (Jelis): a randomised open-label, blinded endpoint analysis. Lancet 369, 1090–1098.
14.Roncaglioni, MC, Tombesi, M, Avanzini, F et al. (2013) N-3 fatty acids in patients with multiple cardiovascular risk factors. N Engl J Med 368, 1800–1808.
15.Bosch, J, Gerstein, HC, Dagenais, GR et al. (2012) N-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med 367, 309–318.
16.Kromhout, D, Giltay, EJ & Geleijnse, JM (2010) N-3 fatty acids and cardiovascular events after myocardial infarction. N Engl J Med 363, 2015–2026.
17.Rizos, EC, Ntzani, EE, Bika, E et al. (2012) Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. JAMA 308, 1024–1033.
18.Aung, T, Halsey, J, Kromhout, D et al. (2018) Associations of omega-3 fatty acid supplement use with cardiovascular disease risks: meta-analysis of 10 trials involving 77917 individuals. JAMA Cardiol. 3, 225–234.
19.Maki, KC & Dicklin, MR (2018) Omega-3 fatty acid supplementation and cardiovascular disease risk: glass half full or time to nail the coffin shut? Nutrients 10, 864.
20.Meyer, BJ & Groot, RHM (2017) Effects of omega-3 long chain polyunsaturated fatty acid supplementation on cardiovascular mortality: the importance of the dose of DHA. Nutrients 9.
21.Harris, WS (2013) Are n-3 fatty acids still cardioprotective? Curr Opin Clin Nutr Metab Care 16, 141–149.
22.Maki, KC, Palacios, OM, Bell, M et al. (2017) Use of supplemental long-chain omega-3 fatty acids and risk for cardiac death: an updated meta-analysis and review of research gaps. J Clin Lipidol 11, 1152–1160.
23.Alexander, DD, Miller, PE, Van Elswyk, ME et al. (2017) A meta-analysis of randomized controlled trials and prospective cohort studies of eicosapentaenoic and docosahexaenoic long-chain omega-3 fatty acids and coronary heart disease risk. Mayo Clin Proc 92, 15–29.
24.Bowman, L, Mafham, M, Wallendszus, K et al. (2018) Effects of n-3 fatty acid supplements in diabetes mellitus. N Engl J Med 379, 1540–1550.
25.Bhatt, DL, Steg, PG, Miller, M et al. (2019) Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med 380, 11–22.
26.Bhatt, DL, Steg, PG, Brinton, EA et al. (2017) Rationale and design of reduce-it: reduction of cardiovascular events with icosapent ethyl-intervention trial. Clin Cardiol 40, 138–148.
27.Manson, JE, Cook, NR, Lee, IM et al. (2019) Marine n-3 fatty acids and prevention of cardiovascular disease and cancer. N Engl J Med 380, 23–32.
28.Heydari, B, Abdullah, S, Pottala, JV et al. (2016) Effect of omega-3 acid ethyl esters on left ventricular remodeling after acute myocardial infarction clinical perspective: the omega-remodel randomized clinical trial. Circulation 134, 378–391.
29.Miller, PE, Van Elswyk, M & Alexander, DD. (2014) Long-chain omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid and blood pressure: a meta-analysis of randomized controlled trials. Am J Hypertens 27, 885–896.
30.Mozaffarian, D, Geelen, A, Brouwer, IA et al. (2005) Effect of fish oil on heart rate in humans: a meta-analysis of randomized controlled trials. Circulation 112, 1945–1952.
31.Balk, EM, Lichtenstein, AH, Chung, M et al. (2006) Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review. Atherosclerosis 189, 19–30.
32.Shaikh, SR, Kinnun, JJ, Leng, X et al. (2015) How polyunsaturated fatty acids modify molecular organization in membranes: insight from NMR studies of model systems. Biochim Biophys Acta 1848, 211–219.
33.Wachira, JK, Larson, MK & Harris, WS. (2014) N-3 fatty acids affect haemostasis but do not increase the risk of bleeding: clinical observations and mechanistic insights. Br J Nutr 111, 1652–1662.
34.Mozaffarian, D & Wu, JH. (2011) Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events. J Am Coll Cardiol 58, 2047–2067.